BiotechTube

Drug: SL-172154

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous Squamous Cell Carcinoma

Conditions

Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

Trial Timeline

Sep 17, 2020 → Apr 8, 2022

NCT ID
NCT04502888

About Drug: SL-172154

Drug: SL-172154 is a phase 1 stage product being developed by Shattuck Labs for Cutaneous Squamous Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04502888. Target conditions include Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04502888Phase 1Terminated

Competing Products

20 competing products in Cutaneous Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
85
ONTAKEisaiApproved
85
E7777 9 mcg/kgEisaiPhase 3
77
ONTAKEisaiApproved
85
MogamulizumabKyowa KirinApproved
85
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
KW-0761 + VorinostatKyowa KirinPhase 3
77
EnzastaurinEli LillyPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
PembrolizumabMerckPhase 2
52
Comparator: vorinostatMerckPre-clinical
23
PembrolizumabMerckPhase 2
52
TR701 FAMerckPhase 2
52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Tulisokibart + PlaceboMerckPhase 2
52
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
52
Pembrolizumab + MogamulizumabMerckPhase 2
52
TR-701 FA + LinezolidMerckPhase 3
77

Other Products from Shattuck Labs

SL-172154 + Azacitidine (AZA) + VenetoclaxPhase 1
25
SL-279252Phase 1
25
SL-172154Phase 1
25
Pegylated Liposomal Doxorubicin + SL-172154 + Mirvetuximab + SL-172154Phase 1
25
SL-325Phase 1
25